Multiple studies, FDA warnings and recalls have pointed to the dangerous side effects of Risperdal. Here is information about some of these research findings and safety alerts:

Since 1999, studies have connected Risperdal to an increased risk of diabetes. Researchers found that about 50% of patients taking Risperdal developed diabetes after 1 year of taking the drug. Diabetes can lead to other serious health problems including stroke, heart attack and other cardiovascular complications.

In 2000, the FDA started to research the possible connection between atypical antipsychotic medications and diabetes. J&J did not give the results from several studies to the agency, revealed the risks for those taking Risperdal.

In June 2011, the FDA issued public safety warning indicating that some physicians and pharmacists had mistaken Risperdal for Requip. The latter is intended for the treatment of a Parkinson’s disease.

In June 2011, Ortho-McNeil-Janssen recalled approximately 16,000 bottles of Risperdal. The reason for this action was a smell from a pesticide in the wooden pallets used to transport the medication..

In April 2013, Plastic and Reconstructive Surgery revealed that gynecomastia also had a negative impact on these adolescents' social interactions, mental state of mind and sense of self worth, which could last a lifetime.

In November 2013, Health Canada and Janssen Inc. issued a safety alert about the risk of intraoperative floppy iris syndrome (IFIS) linked to the use of RISPERDAL®, RISPERDAL® M-TAB®, RISPERDAL® CONSTA® (risperidone), INVEGA® (paliperidone) and INVEGA SUSTENNA® (paliperidone palmitate).

In 2013, one manufacturing lot of Risperdal Consta (sustained release formulation) was also recalled because of alleged mold contamination.


1 (855) 631-1491

Here are some additional red flags concerning the side effects of Risperidone:

  • The Janssen website warns that seniors using long-acting injections of Risperdal Consta are more vulnerable to cardiovascular death. According to the FDA, dementia patients using Risperdal were 1.6 to 1.7 times more likely to die from different health complications including heart disease. The drug has not been approved for the treatment of dementia in seniors.

  • A Department of Veterans Affairs study, published in the Journal of the American Medical Association, indicates that Risperdal may be comparable to the effectiveness of a placebo in treating veterans for post-traumatic stress disorder (PTSD). Findings indicated that 5% of veterans with PTSD who took Risperdal and 5% who were given a placebo reported a complete recovery. The study also found that between 10% and 20% of both groups reported some relief from the disorder. However, the group that took Risperdal experienced more side effects including additional weight.